Discover and read the best of Twitter Threads about #PD1
Most recents (2)
1/ $PVCT’s PV-10 (#RoseBengalSodium) Immuno-Oncology Cycle & PD-1-Combination Mechanism. A #THREAD. #InduceAndBoost.
2/ Over the past decade-plus, cancer immunotherapy with antibodies targeting the PD-1 immune checkpoint pathway (i.e., PD-1 inhibitors #PD1) has yielded dramatic improvement in clinical outcome for many patients with #CutaneousMelanoma. #Keytruda #Opdivo #otherPD1s #PDL1s
3/ However, patients with Stage III disease and, in particular, those with in-transit disease (i.e., in-transit melanoma; ITM #IntransitMelanoma), have presented unique challenges with regard to response rate and durability of response.
CIs didn’t work, so synergy is *non-obvious*
Further, IF ANYTHING, field was maybe suggesting that neoadjuvant was only place it might work. BUT *unexpectedly* adjuvant works best.
Patentability = war, highly competitive, highly lucrative CI market
$NWBO $MRK #PD1 #Checkpoint
Further, IF ANYTHING, field was maybe suggesting that neoadjuvant was only place it might work. BUT *unexpectedly* adjuvant works best.
Patentability = war, highly competitive, highly lucrative CI market
$NWBO $MRK #PD1 #Checkpoint
The combo data reduced this non-obvious, unexpected phenomenon to practice, in my opinion.
1 + 0 = 6
$NWBO $MRK
1 + 0 = 6
$NWBO $MRK
